SG11202005322RA - Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals - Google Patents
Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicalsInfo
- Publication number
- SG11202005322RA SG11202005322RA SG11202005322RA SG11202005322RA SG11202005322RA SG 11202005322R A SG11202005322R A SG 11202005322RA SG 11202005322R A SG11202005322R A SG 11202005322RA SG 11202005322R A SG11202005322R A SG 11202005322RA SG 11202005322R A SG11202005322R A SG 11202005322RA
- Authority
- SG
- Singapore
- Prior art keywords
- injectable solution
- basal insulin
- hydrophobic radicals
- acid carrying
- carboxylate charges
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/2045—Polyamides; Polyaminoacids, e.g. polylysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762606138P | 2017-12-07 | 2017-12-07 | |
FR1761807A FR3074681B1 (en) | 2017-12-07 | 2017-12-07 | PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS |
FR1855934A FR3083088B1 (en) | 2018-06-29 | 2018-06-29 | SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS |
PCT/EP2018/083896 WO2019110773A1 (en) | 2017-12-07 | 2018-12-07 | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005322RA true SG11202005322RA (en) | 2020-07-29 |
Family
ID=64607017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005322RA SG11202005322RA (en) | 2017-12-07 | 2018-12-07 | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190216931A1 (en) |
EP (1) | EP3740229A1 (en) |
JP (1) | JP2021505607A (en) |
KR (1) | KR20200106891A (en) |
CN (1) | CN111727049A (en) |
BR (1) | BR112020011570A2 (en) |
CA (1) | CA3084688A1 (en) |
MA (1) | MA51597A (en) |
SG (1) | SG11202005322RA (en) |
TW (1) | TWI813604B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111683674A (en) * | 2017-12-07 | 2020-09-18 | 阿道恰公司 | Composition in the form of an injectable aqueous solution comprising an amylin, an amylin agonist receptor or an amylin analog and a copoly amino acid |
KR20200106891A (en) | 2017-12-07 | 2020-09-15 | 아도시아 | A solution for injection at pH 7 comprising at least one basal insulin with a pI of 5.8 to 8.5, and a co-polyamino acid bearing a carboxylate charge and a hydrophobic radical |
CN111836616B (en) | 2017-12-07 | 2024-01-16 | 阿道恰公司 | Injectable solution with pH 7 comprising at least one basal insulin with PI between 5.8 and 8.5 and a copolyamino acid with carboxylate charge and hydrophobic group |
US20200179489A1 (en) * | 2018-12-07 | 2020-06-11 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
DE3837825A1 (en) | 1988-11-08 | 1990-05-10 | Hoechst Ag | NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM |
US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
EP1063254A1 (en) | 1999-06-25 | 2000-12-27 | Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung | Copolymers for the transport of nucleic acids in the cell |
FR2801226B1 (en) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION |
FR2827069A1 (en) | 2001-07-03 | 2003-01-10 | Thomson Multimedia Sa | DEVICES AND METHOD FOR PRODUCING MUSIC BASED ON PHYSIOLOGICAL PARAMETERS |
FR2840614B1 (en) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
FR2843117B1 (en) * | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | POLYAMINOACIDS FUNCTIONALIZED BY AT LEAST ONE HYDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
EP1620465A2 (en) | 2003-04-29 | 2006-02-01 | Eli Lilly And Company | Insulin analogs having protracted time action |
FR2855521B1 (en) * | 2003-05-28 | 2005-08-05 | Flamel Tech Sa | POLYAMINOACIDES FUNCTIONALIZED BY AT LEAST ONE YDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS. |
FR2860516B1 (en) * | 2003-10-03 | 2006-01-13 | Flamel Tech Sa | TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
FR2873704B1 (en) | 2004-07-30 | 2006-12-08 | Flamel Technologies Sa | POLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GRAFTS CARRYING AN ANIONIC CHARGE AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS |
FR2885521B1 (en) | 2005-05-10 | 2009-07-24 | Oreal | COSMETIC COMPOSITION |
FR2910318B1 (en) | 2006-12-20 | 2009-07-03 | Flamel Technologies Sa | DISPERSION OF POLYAMINOACIDS IN A CONTINUOUS LIPID PHASE |
EP2078713A1 (en) | 2007-12-28 | 2009-07-15 | QuoNova GmbH | Inhibitors of biofilm formation of gram-positive and gram-negative bacteria |
EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
TWI480070B (en) | 2011-04-21 | 2015-04-11 | Univ Kaohsiung Medical | Conformations of divergent peptides with mineral binding affinity |
AU2012293463B2 (en) | 2011-08-10 | 2016-08-04 | Adocia | Injectable solution of at least one type of basal insulin |
FR2985429B1 (en) * | 2012-01-09 | 2016-07-29 | Adocia | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS |
FR2985428B1 (en) * | 2012-01-09 | 2016-05-27 | Adocia | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACIDE |
BR112014016889A8 (en) * | 2012-01-09 | 2017-07-04 | Adocia | composition in the form of an aqueous injectable solution ph is comprised between 6.0 and 8.0 and unit dose formulation with ph comprised between 7 and 7.8 |
WO2013118895A1 (en) | 2012-02-09 | 2013-08-15 | 味の素株式会社 | Amphoteric ion-type basic amino acid derivative |
US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
FR3001896B1 (en) | 2013-02-12 | 2015-07-03 | Adocia | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER |
AU2013346623A1 (en) | 2012-11-13 | 2015-05-14 | Adocia | Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units |
FR3001895B1 (en) | 2013-02-12 | 2015-07-03 | Adocia | PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS |
US9707275B2 (en) * | 2012-12-19 | 2017-07-18 | Wockhardt Limited | Stable aqueous composition comprising human insulin or an analogue or derivative thereof |
JP2016509912A (en) | 2013-03-15 | 2016-04-04 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Body member and diaphragm material for medical devices |
AU2015212733B2 (en) | 2014-02-03 | 2018-06-07 | Eidgenoessische Technische Hochschule Zurich | Small molecule drug conjugates |
US9682100B2 (en) | 2015-01-26 | 2017-06-20 | International Business Machines Corporation | Cationic polyamines for treatment of viruses |
CN108351374A (en) | 2015-10-22 | 2018-07-31 | 新纳公司 | Expansible average current sensing system |
FR3052072A1 (en) | 2016-06-07 | 2017-12-08 | Adocia | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS |
FR3052071B1 (en) | 2016-06-07 | 2018-09-07 | Adocia | COMPOSITIONS IN THE FORM OF AQUEOUS INJECTABLE SOLUTION COMPRISING GLUCAGON AND A CO-POLYAMINOACID |
BR112018075259A2 (en) | 2016-06-07 | 2019-03-12 | Adocia | composition in the form of an injectable aqueous solution, the pH of which is 6.0 to 8.0 |
CN205959708U (en) | 2016-08-15 | 2017-02-15 | 布里斯克磁业(上海)有限公司 | Magnetic leakage formula magnetic conduction board and magnetic leakage formula magnetism holding device |
US10463717B2 (en) | 2016-12-27 | 2019-11-05 | Adocia | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid |
US11173109B2 (en) | 2017-12-07 | 2021-11-16 | Adocia | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid |
MX2020005913A (en) | 2017-12-07 | 2020-10-19 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals. |
CN111836616B (en) | 2017-12-07 | 2024-01-16 | 阿道恰公司 | Injectable solution with pH 7 comprising at least one basal insulin with PI between 5.8 and 8.5 and a copolyamino acid with carboxylate charge and hydrophobic group |
US20190274953A1 (en) | 2017-12-07 | 2019-09-12 | Adocia | Ph 7 injectable solution comprising at least one basic insulin with a pi comprised from 5.8 to 8.5 and a co-polyaminoacide bearing carboxylate charges and hydrophobic radicals |
KR20200106891A (en) | 2017-12-07 | 2020-09-15 | 아도시아 | A solution for injection at pH 7 comprising at least one basal insulin with a pI of 5.8 to 8.5, and a co-polyamino acid bearing a carboxylate charge and a hydrophobic radical |
US20190388515A1 (en) | 2017-12-07 | 2019-12-26 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the pi of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
CN111683674A (en) * | 2017-12-07 | 2020-09-18 | 阿道恰公司 | Composition in the form of an injectable aqueous solution comprising an amylin, an amylin agonist receptor or an amylin analog and a copoly amino acid |
CN111683675A (en) | 2017-12-07 | 2020-09-18 | 阿道恰公司 | Compositions in the form of injectable aqueous solutions comprising human glucagon and a polyamino acid copolymer |
BR112020011484A2 (en) | 2017-12-07 | 2020-11-17 | Adocia | compositions in the form of an injectable aquatic solution comprising human glucagon and a copolyamino acid |
US20200179489A1 (en) | 2018-12-07 | 2020-06-11 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol |
-
2018
- 2018-12-07 KR KR1020207019244A patent/KR20200106891A/en unknown
- 2018-12-07 EP EP18814899.3A patent/EP3740229A1/en active Pending
- 2018-12-07 SG SG11202005322RA patent/SG11202005322RA/en unknown
- 2018-12-07 TW TW107144180A patent/TWI813604B/en active
- 2018-12-07 BR BR112020011570-3A patent/BR112020011570A2/en unknown
- 2018-12-07 JP JP2020531052A patent/JP2021505607A/en active Pending
- 2018-12-07 CA CA3084688A patent/CA3084688A1/en active Pending
- 2018-12-07 US US16/213,809 patent/US20190216931A1/en not_active Abandoned
- 2018-12-07 MA MA051597A patent/MA51597A/en unknown
- 2018-12-07 CN CN201880088456.4A patent/CN111727049A/en active Pending
-
2020
- 2020-06-15 US US16/902,176 patent/US11883496B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3084688A1 (en) | 2019-06-13 |
JP2021505607A (en) | 2021-02-18 |
KR20200106891A (en) | 2020-09-15 |
BR112020011570A2 (en) | 2020-12-08 |
MA51597A (en) | 2020-11-25 |
EP3740229A1 (en) | 2020-11-25 |
US20190216931A1 (en) | 2019-07-18 |
TWI813604B (en) | 2023-09-01 |
TW201938189A (en) | 2019-10-01 |
CN111727049A (en) | 2020-09-29 |
US20200306379A1 (en) | 2020-10-01 |
US11883496B2 (en) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275192A (en) | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals | |
IL275148A (en) | Injectable solution with a ph of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals | |
SG11202005322RA (en) | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals | |
HK1248607A1 (en) | Injectable solution at ph 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid | |
SA518400588B1 (en) | Injectable Solution at PH 7 Comprising at Least One Basal Insulin The PI of Which is From 5.8 to 8.5 and A Co-Polyamino Acid Bearing Carboxylate Charges and Hydrophobic Radicals | |
IL263256B (en) | Blood pump assembly having a sensor and a sensor shield | |
HK1247089A1 (en) | Copositions and methods for activing "stimulator of interferon gene"-dependent signalling | |
IL255155A0 (en) | Glucose-responsive insulin delivery system using hypoxia-sensitive nanocomposites | |
MX2018015070A (en) | Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid. | |
ZA201904303B (en) | Computer-implemented system and method for determining the state of a machine executable contract implemented using a blockchain | |
IL272141A (en) | Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor | |
EP3506171A4 (en) | Implantable electronic tag for tire and assembly process | |
HK1253566A1 (en) | System and method for syringe plunger engagement with an injector | |
IL279445A (en) | Stabilized hyaluronic acid | |
PH12020550828A1 (en) | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid | |
GB201804043D0 (en) | Infusion systems and method | |
EP3362672A4 (en) | Method of modifying a conventional direct injector and modified injector assembly | |
GB201710099D0 (en) | Methods and systems to identify smart sensor locations by the application of physical stimulus | |
GB201805072D0 (en) | EGR urea hydrolysis | |
EP3231432A4 (en) | Agent for hypodermic injections and production method for syringes containing agent for hypodermic injections | |
GB201700555D0 (en) | Method for the treatment of a relapsing-remitting condition | |
EP3831428A4 (en) | Pre-filled syringe and pre-filled syringe production method | |
IL238908A (en) | Pesticide for the extermination of blattodea and method for production thereof | |
EP3831429A4 (en) | Pre-filled syringe and pre-filled syringe production method | |
AU201714197S (en) | Hypodermic syringes |